Do you know that studies have shown that probiotics goes beyond gut health? Learn more from Dr. Anders Henriksson, Principal Application Specialist through his presentation at the Food for Health Conference held in conjunction with UMass 100th anniversary.

1. Role of the human gut microbiome
in digestive health and beyond
Dr. Anders Henriksson
Principal Application Specialist
DuPont Nutrition & Health, Australia, New Zealand
January 2018

2. Overview
The human gut microbiome and its contribution to colonization
resistance and digestive health
The possible role of probiotics in reducing the prevalence and
severity of non-communicable diseases
• Possible role of probiotics in slowing the progression of insulin
resistance and reducing the prevalence of gestational diabetes
• Role of probiotics in management of other conditions related to
the metabolic syndrome

3. Probiotics in management of on Antibiotic Associated
Diarrhea in adults
AIM OF THE STUDY
This study was designed to determine the dose response effect of
HOWARU® Restore formulation on the incidence of AAD and CDAD and
severity of gastrointestinal symptoms in adults having antibiotherapy.
STUDY DESIGN
Triple blind, randomised, placebo controled
SUBJECTS
Adults in-patients requiring antibiotherapy.
450 PATIENTS DIVIDED IN 3 TREATMENT GROUPS
COMPLETED THE STUDY
• Placebo
• HOWARU® Restore low dose (4.17 x 109 CFU/day)
• HOWARU® Restore high dose (1.70 x 1010 CFU/day)
3

4. Probiotics in management of on Antibiotic Associated
Diarrhea in adults - incidence
4
24,6%
19,6%
12,5%
Placebo Low dose High dose
Subjects taking the high dose HOWARU® Restore treatment has experienced a 50%
reduction in incidence of AAD compared to the placebo group (p<0.005).
Low dose HOWARU® Restore group has shown a 20% reduction compared to
placebo group but the results were not statistically significant.
*

6. Effect of Lactobacillus rhamnosus HN001™ on the
prevalence of gestational diabetes trial design in brief
Placebo group
n = 211
Probiotic group
n = 212
Capsules with maltodextrin
Capsules with 6.0E+09 CFU of HN001™
Assessment of gestational
diabetes at 14-16 weeks
gestation
Assessment of gestational
diabetes at 24-30 weeks
gestation

7. TM
TM

8. Probiotics and prebiotics for controlling body fat mass
Randomized, double-blind, multicenter study
Study design and execution follows ICH-GCP
225 Finnish participants with BMI 28-34.9, otherwise healthy
Primary outcome: relative change in body fat mass
Stenman et al. EBioMedicine 2016 ClinicalTrials.gov NCT01978691
HOWARU® Shape – Unique clinical study
6Months
Follow-up:
+1 month
Control: microcrystalline cellulose (MCC = 12g/day)
Probiotic: B‐420™ (1010 CFU/day) + MCC (12g/day)
Prebiotic: Litesse® Ultra™ polydextrose (12g/day)
Synbiotic: Litesse® Ultra™ (12g/day) + B‐420™ (1010 CFU/day)
Baseline

9. 1.4 kg reduction of total Body Fat Mass compared to placebo…
Stenman et al. EBioMedicine 2016
Primary outcome: B‐420™ + Litesse® Ultra™ control total body fat mass
‐4.5% (‐1.4 kg)
in fat mass
P=0.02
‐4% (‐1.4 kg)
In fat mass
Statistical analyses:
ANCOVA values
Factorial analysis

10. Summary
The human gut microbiome contributes to colonization resistance and
digestive health in numerous ways
Parts of the human gut microbiome may affect the onset and progression
of a range of non-communicable diseases
• Lactobacillus rhamnosus HN001TM may reduce the prevalence of
gestational diabetes
• Bifidobacterium lactis B420TM may reduce the prevalence and
severity of other symptoms of the metabolic syndrome, including
gains of body fat mass

11. Copyright © 2017 DuPont or its affiliates. All rights reserved. The DuPont Oval Logo, DuPont™, The miracles of science™, Danisco® and all products denoted with ™ or ®
are registered trademarks or trademarks of E. I. du Pont de Nemours and Company or its affiliates.
DuPont Nutrition & Health combines in-depth knowledge of food and
nutrition with current research and expert science to deliver
unmatched value to the food, beverage and dietary supplement
industries.
We are innovative solvers, drawing on deep consumer insights
and a broad product portfolio to help our customers turn challenges
into high-value business opportunities
Copyright © 2018 DuPont or its affiliates. All rights reserved. The DuPont Oval Logo, DuPont™, The miracles of science™, Danisco® and all products denoted with™ or ® are registered
trademarks or trademarks of E.I. du Pont de Nemours and Company or its affiliates.